[
  {
    "ts": "2025-11-06T04:03:23+00:00",
    "headline": "3 Reasons Investors Love Merck (MRK)",
    "summary": "Although Merck (currently trading at $84.57 per share) has gained 7% over the last six months, it has trailed the S&P 500’s 21.3% return during that period. This may have investors wondering how to approach the situation.",
    "url": "https://finance.yahoo.com/news/3-reasons-investors-love-merck-040323903.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "bb529f8e-bc5a-38ac-92b3-2426b97f79ec",
      "content": {
        "id": "bb529f8e-bc5a-38ac-92b3-2426b97f79ec",
        "contentType": "STORY",
        "title": "3 Reasons Investors Love Merck (MRK)",
        "description": "",
        "summary": "Although Merck (currently trading at $84.57 per share) has gained 7% over the last six months, it has trailed the S&P 500’s 21.3% return during that period. This may have investors wondering how to approach the situation.",
        "pubDate": "2025-11-06T04:03:23Z",
        "displayTime": "2025-11-06T04:03:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/ebe2be3c9f70cfc1092fc0a56a0c75dc",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "MRK Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PqkkAVnP2lidjvyb58UUUQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/ebe2be3c9f70cfc1092fc0a56a0c75dc.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jUpD9l9St2LHULbO70D5fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/ebe2be3c9f70cfc1092fc0a56a0c75dc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-investors-love-merck-040323903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-investors-love-merck-040323903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:51:28+00:00",
    "headline": "AstraZeneca CEO bullish on record revenue numbers and US growth",
    "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
    "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
      "content": {
        "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
        "contentType": "VIDEO",
        "title": "AstraZeneca CEO bullish on record revenue numbers and US growth",
        "description": "<p>AstraZeneca's (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/AZN\">AZN</a>, <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.L\">AZN.L</a>, <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.ST\">AZN.ST</a>) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/JNJ\">JNJ</a>), Merck (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/MRK\">MRK</a>) and Pfizer (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>). For more live coverage of the markets, watch the full episode of <em>Market Sunrise</em> and visit<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/\"> Yahoo Finance</a>.</p>",
        "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
        "pubDate": "2025-11-06T12:51:28Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab",
          "originalWidth": 4787,
          "originalHeight": 2695,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YZigCM3MtAH584LADKiEmA--~B/aD0yNjk1O3c9NDc4NzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 4787,
              "height": 2695,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lb3cKjiVc_C_ZhL48TzyZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]